These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7945447)

  • 1. Suppression of H-ras-mediated transformation in NIH3T3 cells by a ras ribozyme.
    Funato T; Shitara T; Tone T; Jiao L; Kashani-Sabet M; Scanlon KJ
    Biochem Pharmacol; 1994 Oct; 48(7):1471-5. PubMed ID: 7945447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme.
    Kashani-Sabet M; Funato T; Florenes VA; Fodstad O; Scanlon KJ
    Cancer Res; 1994 Feb; 54(4):900-2. PubMed ID: 8313379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A ribozyme specifically suppresses transformation and tumorigenicity of Ha-ras-oncogene-transformed NIH/3T3 cell lines.
    Chang MY; Won SJ; Liu HS
    J Cancer Res Clin Oncol; 1997; 123(2):91-9. PubMed ID: 9030247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribozymes designed to inhibit transformation of NIH3T3 cells by the activated c-Ha-ras gene.
    Koizumi M; Kamiya H; Ohtsuka E
    Gene; 1992 Aug; 117(2):179-84. PubMed ID: 1639266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Ribozyme targeted the point-mutation of activated oncogene inhibits its expression in vivo].
    Liu G; Chen Y; Zhao X; Dong Y; Chen D
    Yi Chuan Xue Bao; 1996; 23(6):477-85. PubMed ID: 9084224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes.
    Ohta Y; Kijima H; Kashani-Sabet M; Scanlon KJ
    J Invest Dermatol; 1996 Feb; 106(2):275-80. PubMed ID: 8601728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of the malignant phenotype by an anti-ras ribozyme.
    Kashani-Sabet M; Funato T; Tone T; Jiao L; Wang W; Yoshida E; Kashfinn BI; Shitara T; Wu AM; Moreno JG
    Antisense Res Dev; 1992; 2(1):3-15. PubMed ID: 1422085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of oncogene-mediated transformation by ectopic expression of p21Waf1 in NIH3T3 cells.
    Michieli P; Li W; Lorenzi MV; Miki T; Zakut R; Givol D; Pierce JH
    Oncogene; 1996 Feb; 12(4):775-84. PubMed ID: 8632899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hammerhead ribozyme-mediated inactivation of mutant RET in medullary thyroid carcinoma.
    Parthasarathy R; Cote GJ; Gagel RF
    Cancer Res; 1999 Aug; 59(16):3911-4. PubMed ID: 10463581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme.
    Feng M; Cabrera G; Deshane J; Scanlon KJ; Curiel DT
    Cancer Res; 1995 May; 55(10):2024-8. PubMed ID: 7743496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of EJ cells tumorigenicity.
    Tone T; Kashani-Sabet M; Funato T; Shitara T; Yoshida E; Kashfian BI; Horng M; Fodstadt O; Scanlon KJ
    In Vivo; 1993; 7(6A):471-6. PubMed ID: 8193263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of c-Ha-ras gene expression by hammerhead ribozymes containing a stable C(UUCG)G hairpin loop.
    Koizumi M; Kamiya H; Ohtsuka E
    Biol Pharm Bull; 1993 Sep; 16(9):879-83. PubMed ID: 8268855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzymatic and antisense effects of a specific anti-Ki-ras ribozyme in vitro and in cell culture.
    Giannini CD; Roth WK; Piiper A; Zeuzem S
    Nucleic Acids Res; 1999 Jul; 27(13):2737-44. PubMed ID: 10373591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribozyme as an approach for growth suppression of human pancreatic cancer.
    Kijima H; Scanlon KJ
    Mol Biotechnol; 2000 Jan; 14(1):59-72. PubMed ID: 10911615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipain-induced suppression of oncogene expression in H-ras-transformed NIH3T3 cells.
    Cox LR; Motz J; Troll W; Garte SJ
    Cancer Res; 1991 Sep; 51(18):4810-4. PubMed ID: 1893373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA.
    Halatsch ME; Schmidt U; Bötefür IC; Holland JF; Ohnuma T
    J Neurosurg; 2000 Feb; 92(2):297-305. PubMed ID: 10659018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell lines containing and expressing the human herpesvirus 6A ts gene are protected from both H-ras and BPV-1 transformation.
    Araujo JC; Doniger J; Stöppler H; Sadaie MR; Rosenthal LJ
    Oncogene; 1997 Feb; 14(8):937-43. PubMed ID: 9050993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant adenovirus encoding H-ras ribozyme induces apoptosis in laryngeal cancer cells through caspase- and mitochondria-dependent pathways.
    Wang CH; Tsai LJ; Tsao YP; Hsieh JT; Chien WW; Liao CL; Wang HW; Liu HS; Chen SL
    Biochem Biophys Res Commun; 2002 Nov; 298(5):805-14. PubMed ID: 12419327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor inhibitory activity of anti-ras ribozymes delivered by retroviral gene transfer.
    Li M; Lonial H; Citarella R; Lindh D; Colina L; Kramer R
    Cancer Gene Ther; 1996; 3(4):221-9. PubMed ID: 8853546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human retinoblastoma gene product prevents c-Ha-ras oncogene mediated cellular transformation of mouse fibroblasts.
    Kivinen L; Pitkänen K; Laiho M
    Oncogene; 1993 Oct; 8(10):2703-11. PubMed ID: 8378082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.